Biosimilar Rules Likely To Survive ACA Battle, Lawyers Say
Amid the ongoing uncertainty over the future of the Affordable Care Act, its provisions for licensing biosimilar products will likely remain in place in light of concerns over escalating drug prices...To view the full article, register now.
Already a subscriber? Click here to view full article